Revenue
2018
2019
2020
2021
2022
2023
2024
2025
BICYCLE THERAPEUTICS PLC (BCYC)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $72.6M | $35.3M | $27.0M | $14.5M | $11.7M | $10.4M | $13.8M | $7.1M | $2.1M |
| Research & development | $240.3M | $173.0M | $156.5M | $81.6M | $44.9M | $33.1M | $25.5M | $20.8M | $11.9M |
| Operating expenses | $319.7M | $245.1M | $216.9M | $131.1M | $77.3M | $62.4M | $40.1M | $28.9M | $18.3M |
| Operating income | −$247.1M | −$209.9M | −$189.9M | −$116.7M | −$65.6M | −$52.0M | −$26.3M | −$21.7M | −$16.2M |
| EBITDAderived | −$240.6M | −$202.7M | −$183.4M | −$113.0M | −$64.2M | −$50.7M | −$25.3M | −$21.0M | −$15.9M |
| Net income | −$219.0M | −$169.0M | −$180.7M | −$112.7M | −$66.8M | −$51.0M | −$30.6M | −$21.8M | −$16.3M |
| Basic EPSper diluted share | -$3.16 | -$2.90 | -$5.08 | -$3.80 | -$2.67 | -$2.66 | -$2.77 | -$49.78 | -$48.81 |
| Diluted EPSper diluted share | -$3.16 | -$2.90 | -$5.08 | -$3.80 | -$2.67 | -$2.66 | -$2.77 | -$49.78 | -$48.81 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 6, 2026Form 4 · 10b5-1 | Perry Jennifer ScottChief Operating Officer | SellOrdinary Shares | 333 | $5.04 | $1.7K | 92.5K |
| Apr 6, 2026Form 4 · 10b5-1 | Perry Jennifer ScottChief Operating Officer | SellOrdinary Shares | 37 | $5.05 | $186.85 | 92.8K |
| Apr 6, 2026Form 4 | Hannay Michael Charles FergusonCHIEF PROD & SUPPLY CHAIN OFF | SellOrdinary Shares | 251 | $5.05 | $1.3K | 96.1K |
| Apr 6, 2026Form 4 | Thompson Travis AlvinChief Financial Officer | SellOrdinary Shares | 102 | $5.05 | $515.10 | 65.4K |
| Apr 6, 2026Form 4 | Lee KevinCHIEF EXECUTIVE OFFICER | SellOrdinary Shares | 1.7K | $5.05 | $8.7K | 611.3K |